Intra-Cellular Therapies（NASDAQ:ITCI）報告季度每股虧損$(0.16)，未達到分析師一致預期的$(0.11)，差異爲45.45%。相比去年同期的每股虧損$(0.29)，這是44.83%的改善。公司報告季度銷售額爲$1.9922億，超過分析師一致預期的$1.934億，超出3.01%。相比去年同期銷售額$1.321億，這是50.81%的增長。

以上內容來自Benzinga Earnings專欄，原文如下：

Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 44.83 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $199.22 million which beat the analyst consensus estimate of $193.40 million by 3.01 percent. This is a 50.81 percent increase over sales of $132.10 million the same period last year.